| Name | Title | Contact Details |
|---|---|---|
Melissa Epstein |
Associate Director, Total Rewards | Profile |
Kelly Schick |
Chief People Officer | Profile |
William McKee |
Interim Chief Financial Officer | Profile |
Lauren White |
Chief Financial Officer | Profile |
Krissy Zambouras |
Director, Human Resources | Profile |
NitroMed, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
BioGenex Laboratories, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Network Biosystems, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Frontier Medicines is a pre-clinical stage biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. According to the American Cancer Society, 1,762,000 new cancer cases and 607,000 deaths from cancer are expected to occur in the US in 2019. Our focus is developing treatments against important cancer-causing proteins that the biopharma industry hasn`t found a way to treat (or “drug”) with pharmaceutical interventions. After decades of research, this has become one of the most critical challenges in addressing human disease and advancing oncology therapy --central to the research at Frontier Medicines. Frontier Medicines is using chemoproteomics – an innovative approach to chemically interrogate proteins in living systems – to discover and pharmacologically target new binding pockets (or “hotspots”) on proteins, making them accessible to small-molecule drug discovery and development. The company`s proprietary chemoproteomics platform also integrates advanced computational approaches and machine learning to further accelerate the path to drug discovery.